MX2022003585A - Metodos para tratar hiperfenilalaninemia. - Google Patents

Metodos para tratar hiperfenilalaninemia.

Info

Publication number
MX2022003585A
MX2022003585A MX2022003585A MX2022003585A MX2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A
Authority
MX
Mexico
Prior art keywords
methods
hyperphenylalaninemia
treating
treating hyperphenylalaninemia
sepiapterin
Prior art date
Application number
MX2022003585A
Other languages
English (en)
Inventor
Niel Smith
Original Assignee
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc filed Critical Ptc Therapeutics Mp Inc
Publication of MX2022003585A publication Critical patent/MX2022003585A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención presenta métodos para reducir la concentración de fenilalanina en sangre en un sujeto por la administración de sepiapterina, o una sal farmacéuticamente aceptable de la misma.
MX2022003585A 2019-09-25 2020-09-25 Metodos para tratar hiperfenilalaninemia. MX2022003585A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962905720P 2019-09-25 2019-09-25
PCT/US2020/052871 WO2021062264A1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia

Publications (1)

Publication Number Publication Date
MX2022003585A true MX2022003585A (es) 2022-04-19

Family

ID=72827023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003585A MX2022003585A (es) 2019-09-25 2020-09-25 Metodos para tratar hiperfenilalaninemia.

Country Status (12)

Country Link
US (1) US20220362249A1 (es)
EP (1) EP4034122A1 (es)
JP (1) JP2022549834A (es)
KR (1) KR20220070477A (es)
CN (1) CN114650825A (es)
AU (1) AU2020353676A1 (es)
BR (1) BR112022003719A2 (es)
CA (1) CA3150003A1 (es)
IL (1) IL291565A (es)
JO (1) JOP20220042A1 (es)
MX (1) MX2022003585A (es)
WO (1) WO2021062264A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019010222A8 (pt) 2016-11-29 2022-11-22 Censa Pharmaceuticals Inc Polimorfos de sepiapterina e sais dos mesmos
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF
CN112703002A (zh) 2018-05-30 2021-04-23 Ptc医疗Mp公司 增加墨蝶呤血浆暴露的方法
US20210161901A1 (en) * 2018-05-30 2021-06-03 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
HUE030221T2 (en) * 2014-03-31 2017-04-28 Vasopharm Gmbh Solid pharmaceutical composition containing biopterin derivatives and uses of such compositions
BR112019010222A8 (pt) 2016-11-29 2022-11-22 Censa Pharmaceuticals Inc Polimorfos de sepiapterina e sais dos mesmos
EP3548487A4 (en) 2016-11-29 2020-04-29 Censa Pharmaceuticals Inc. POLYMORPHE SHAPE OF SEPIAPTERIN
WO2019046849A1 (en) * 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF
AU2019277372A1 (en) 2018-05-30 2021-01-21 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin

Also Published As

Publication number Publication date
JOP20220042A1 (ar) 2023-01-30
EP4034122A1 (en) 2022-08-03
CA3150003A1 (en) 2021-04-01
KR20220070477A (ko) 2022-05-31
US20220362249A1 (en) 2022-11-17
CN114650825A (zh) 2022-06-21
IL291565A (en) 2022-05-01
WO2021062264A1 (en) 2021-04-01
JP2022549834A (ja) 2022-11-29
BR112022003719A2 (pt) 2022-05-31
AU2020353676A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
MX2022003585A (es) Metodos para tratar hiperfenilalaninemia.
ZA202202097B (en) Amino pyrimidine ssao inhibitors
CY1124789T1 (el) Πυριμιδιν-2-υλαμινο-1η-πυραζολια ως αναστολεις lrrk2 για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
SG10201902598VA (en) Peptidomimetic macrocycles and formulations thereof
NZ739503A (en) A novel approach for treatment of cancer using immunomodulation
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
MX2018003657A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan el adn e inhibidores de proteina relacionada con ataxia telangiectasia y rad3 (atr).
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2018013271A (es) Compuestos 9-aminometil minociclina y metodos para utilizarlos en el tratamiento de infeccion de vias urinarias (ivu).
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2020011453A (es) Combinaciones para tratar el cancer.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2021012824A (es) Métodos para tratar el prurito.
PH12019501566A1 (en) Amide compounds and use thereof
MX2022005951A (es) Compuestos de pirrolotriazina que actuan como inhibidor de mnk.
MX2019002077A (es) Formas cristalinas y formas de sal de compuestos de 7h-pirrolo[2,3-d]pirimidina y metodo de preparacion de las mismas.
MX2019004602A (es) Agentes anti-proliferativos para tratar pah.
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.
MX2023009272A (es) Métodos para tratar los glioblastomas con sepiapterina.
MX2017014731A (es) Eliminacion de linfocitos b como marcador diagnostico.